CORONA Remedies
CORONA · Pharma > Pharmaceuticals & Drugs Listing date: Dec. 15, 2025

Stock Price vs Company Growth
1d
0.8%
1w
5.7%
1m
12.3%
all
12.3%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 1,614 0.8%
1,337
1,659
Company Overview

Sales
1,315 Cr
Growth: 7.1%
Profit after Tax
182 Cr
Growth: -0.9%
Mid Cap
9,872 Cr
P/E: 54.4x
Industry P/E: 29.7x
Fundamentals

Sales (Cr) ₹ 1,315
Growth 7.1%
EBITDA 22.6%
P/S 7.5x
Dividend 0.0%
P/E 54.4x
Book Value ₹ 10
PEG Ratio 7.7x
ROE 296.8%
P/B N/A
Shareholding Pattern

Increase    Decrease    No change
Company Profile Detailed

The company is primarily engaged in the business of manufacturing, trading and marketing of pharmaceutical products. The company also has an associate which is involved in similar line of business. Its diversified product portfolio comprises brands that cater to a range of therapeutic areas such as women’s healthcare, cardio-diabeto, pain management, urology and others/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory.
Belongs to (2 Indices)